Frost & Sullivan Independent Equity Research

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59


Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Immediate Report

Published on: 31 July, 2018

RedHill research articles: